Grifols SA
ISIN ES0171996087
|WKN A2ABUQ
Overview
Description
Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma Segment includes all activities related with products deriving from human plasma for therapeutic use. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.
Healthcare Biopharmaceuticals Other Biopharmaceuticals Spain
Financials
Key metrics
| Market capitalisation, EUR | 4,900.31 m |
| EPS, EUR | - |
| P/B ratio | 0.91 |
| P/E ratio | 34.17 |
| Dividend yield | 0.00% |
Income statement (2024)
| Revenue, EUR | 7,212.38 m |
| Net income, EUR | 156.92 m |
| Profit margin | 2.18% |
What ETF is Grifols SA in?
There are 207 ETFs which contain Grifols SA. All of these ETFs are listed in the table below. The ETF with the largest weighting of Grifols SA is the BNP Paribas Easy ECPI Global ESG Med Tech UCITS ETF USD.
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.
Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.
Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.
